Your browser doesn't support javascript.
loading
Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study.
García-Alfonso, Pilar; Muñoz, Andrés; Jiménez-Castro, Jerónimo; Jiménez-Fonseca, Paula; Pericay, Carles; Longo-Muñoz, Federico; Reyna-Fortes, Carmen; Argilés-Martínez, Guillem; González-Astorga, Beatriz; Gómez-Reina, María José; Ruiz-Casado, Ana; Rodríguez-Salas, Nuria; López-López, Rafael; Carmona-Bayonas, Alberto; Conde-Herrero, Verónica; Aranda, Enrique.
Afiliación
  • García-Alfonso P; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
  • Muñoz A; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
  • Jiménez-Castro J; Department of Medical Oncology, Hospital Universitario Virgen del Rocío, 41013 Seville, Spain.
  • Jiménez-Fonseca P; Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, 33011 Oviedo, Spain.
  • Pericay C; Department of Medical Oncology, Hospital Universitari Parc Taulí, 08208 Sabadell, Spain.
  • Longo-Muñoz F; Department of Medical Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
  • Reyna-Fortes C; Department of Medical Oncology, UGC Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, 29010 Málaga, Spain.
  • Argilés-Martínez G; Department of Medical Oncology, Hospital Universitari Vall d'Hebrón, 08035 Barcelona, Spain.
  • González-Astorga B; Department of Medical Oncology, Hospital Universitario Clínico San Cecilio, 18016 Granada, Spain.
  • Gómez-Reina MJ; Department of Medical Oncology, Hospital Universitario Puerta del Mar, 11009 Cádiz, Spain.
  • Ruiz-Casado A; Department of Medical Oncology, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Majadahonda, Spain.
  • Rodríguez-Salas N; Department of Medical Oncology, Hospital Universitario La Paz, CIBERONC, 28046 Madrid, Spain.
  • López-López R; Translational Medical Oncology Group, Department of Medical Oncology, Hospital Clínico Universitario e Instituto de Investigación Sanitaria (IDIS), CIBERONC, Facultad de Medicina de la Universidad de Santiago de Compostela, 15706 Santiago de Compostela, Spain.
  • Carmona-Bayonas A; Department of Medical Oncology, Hospital General Universitario Morales Meseguer, 30008 Murcia, Spain.
  • Conde-Herrero V; Department of Medical Oncology, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
  • Aranda E; Department of Medical Oncology, Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, 14004 Córdoba, Spain.
Cancers (Basel) ; 13(18)2021 Sep 08.
Article en En | MEDLINE | ID: mdl-34572740
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article